Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
FDA Calls for Restrictions on Ovarian Cancer Drug Rubraca Due to High Mortality Rates If the drug maker Clovis does not update the Rubraca label, the FDA may seek third party recommendations on whether to remove Rubraca from the market November 18, 2022 Irvin Jackson Add Your Comments Federal health officials are calling for the drug maker Clovis to limit the use of its ovarian cancer medication, Rubraca, following new clinical trial data that suggests side effects may increase the risk of death among patients with certain types of aggressive ovarian cancer. Rubraca (rucaparib) is a new-generation cancer medicine introduced by Clovis Oncology in April 2018, which interferes with the growth and spread of cancer cells in the body. The drug was approved by the U.S. Food and Drug Administration (FDA) as a second-line maintenance treatment for patients with BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies. The drug is part of a class of medications which provide targeted therapy known as a PARP inhibitor, which works by blocking an enzyme that helps repair damaged DNA and to helps to kill cancer cells and shrink tumors. While early clinical trial data on Rubraca provided to the FDA showed tumor progression benefits when compared with a placebo, post-marketing clinical trials involving additional patient data has shown Rubraca may increase death rates among users. Rubraca Side Effects Increased Risk of Death The findings of a phase 3 clinical trial, ARIEL3, were presented at this year’s International Gynecologic Cancer Society, indicating that ovarian cancer patients with elevated levels of genetic abnormalities taking Rubraca faced a 28% increased risk of mortality when compared to those in the placebo group. The data further indicated patients being treated with Rubraca that did not have BRCA mutations faced a 15% increased risk of death when comparted to those in the placebo group. After reviewing the results of the available data, the FDA scheduled a meeting with Clovis Oncology on November 14, which was held by teleconference to discuss the overall survival (OS) data from the Company’s ARIEL3 clinical trial. Based on the negative findings, the FDA is now calling for Clovis to voluntarily revise the label to limit the indication of Rubraca in this second-line maintenance treatment to tBRCA patients only, in an effort to reduce the probability of death. Do You Know about… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION The FDA’s recommendation was reinforced by a strong message to Clovis, indicating that if the company fails to follow the recommendation, the agency would be forced to convene an Oncologic Drugs Advisory Committee (ODAC) meeting to further review the findings and establish seek third party expert recommendations on whether the drug should remain available on the market for its currently approved use. At this time, Clovis has yet to issue a formal response and is reportedly still evaluating the terms of the FDA’s request and whether the company will comply with the recommendation. Clovis Oncology May Be Near Bankruptcy Reports have suggested that Clovis Oncology, Inc. may be headed for bankruptcy in the coming months, following a September 2022 filing with the Securities Exchange Commission indicating the company may not be able to continue operations beyond a year of the filing. The manufacturer stated that ongoing concerns about the FDA’s investigation into Rubraca’s overall survival rate, in addition to significant net losses since inception, raised doubt about Clovis’s ability to continue operations throughout 2023. “Based on our current cash and cash equivalents, together with current estimates for revenues to be generated by sales of Rubraca, we will not have sufficient liquidity to maintain our operations beyond January 2023”, Clovis stated in its Quarterly Report. Tags: Clinical Trials, Clovis, Drug Side Effects, Ovarian Cancer, Rubraca Image Credit: | More Lawsuit Stories Radiation from CT Scans Given in 2023 Alone May Cause More Than 100,000 Future Cancer Cases: Study April 18, 2025 Ford Recall Issued Due to Potential for Brake Loss in Certain Trucks and SUVs April 18, 2025 More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies April 17, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies (Posted: yesterday) Nearly a dozen different cosmetics companies face more than 12,000 hair relaxer lawsuits, involving claims that chemical straighteners caused women to develop uterine cancer, endometrial cancer, ovarian cancer and other injuries. MORE ABOUT: HAIR RELAXER LAWSUITUterine and Endometrial Cancer Caused by Hair Relaxer Products: Lawsuit (03/25/2025)Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (03/13/2025)Synthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025) Paraquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (Posted: 2 days ago) Lawyers involved in Paraquat Parkinson’s disease lawsuits pending in the federal court system indicate that they have reached an agreement to settle many of the claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSAppeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)Farmers Exposed to Certain Pesticides Face an Increased Risk of Rheumatoid Arthritis (12/11/2024) Status of Suboxone Tooth Loss Lawsuits To Be Reviewed at MDL Conference (Posted: 2 days ago) A federal judge will meet with lawyers involved with Suboxone tooth loss lawsuits tomorrow, to review the status of pretrial proceedings in claims brought by individuals throughout the U.S. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUITPrenatal Opioid Exposure May Result in Smaller Brains Among Newborns: Study (04/14/2025)Suboxone Lawsuit Filing Deadline Nears for Many Tooth Decay Claims in 3-Year SOL States (04/07/2025)Up to 100 Suboxone Tooth Decay Claims Can Be Filed on Single Lawsuit in MDL: Judge (03/17/2025)
Radiation from CT Scans Given in 2023 Alone May Cause More Than 100,000 Future Cancer Cases: Study April 18, 2025
More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies April 17, 2025
More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies (Posted: yesterday) Nearly a dozen different cosmetics companies face more than 12,000 hair relaxer lawsuits, involving claims that chemical straighteners caused women to develop uterine cancer, endometrial cancer, ovarian cancer and other injuries. MORE ABOUT: HAIR RELAXER LAWSUITUterine and Endometrial Cancer Caused by Hair Relaxer Products: Lawsuit (03/25/2025)Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (03/13/2025)Synthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)
Paraquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (Posted: 2 days ago) Lawyers involved in Paraquat Parkinson’s disease lawsuits pending in the federal court system indicate that they have reached an agreement to settle many of the claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSAppeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)Farmers Exposed to Certain Pesticides Face an Increased Risk of Rheumatoid Arthritis (12/11/2024)
Status of Suboxone Tooth Loss Lawsuits To Be Reviewed at MDL Conference (Posted: 2 days ago) A federal judge will meet with lawyers involved with Suboxone tooth loss lawsuits tomorrow, to review the status of pretrial proceedings in claims brought by individuals throughout the U.S. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUITPrenatal Opioid Exposure May Result in Smaller Brains Among Newborns: Study (04/14/2025)Suboxone Lawsuit Filing Deadline Nears for Many Tooth Decay Claims in 3-Year SOL States (04/07/2025)Up to 100 Suboxone Tooth Decay Claims Can Be Filed on Single Lawsuit in MDL: Judge (03/17/2025)